Related Experiment Videos
[Oxprenol and platelet aggregation (author's transl)]
Giornale Italiano Di Cardiologia
|May 1, 1978
Insights
Oxprenolol administration in coronary artery disease patients did not significantly alter platelet aggregation induced by ADP or adrenaline. This study examined effects at various time points post-infusion.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Platelet aggregation plays a crucial role in thrombotic events associated with coronary artery disease.
- Understanding the impact of beta-blockers on platelet function is important for managing cardiovascular risk.
Purpose:
- To investigate the effect of a 6 mg dose of oxprenolol on platelet aggregation in patients with coronary artery disease.
- To assess these effects at multiple time points following drug administration.
Summary:
- Platelet aggregation was measured in coronary artery disease patients before and up to 5 hours after a 6 mg oxprenolol infusion.
- Aggregation was stimulated using adenosine diphosphate (ADP) and adrenaline.
- No significant changes in platelet aggregation were observed in response to either stimulus.
Impact:
- The findings suggest that oxprenolol, at the tested dosage, may not significantly impact platelet activity relevant to acute thrombotic events in this patient group.
- Further research may explore different dosages or patient populations.
Abstract:
The effect on the platelet aggregation of the administration of 6 mg of oxprenolol has been studied in patients suffering from coronary artery disease. Four samples were collected: a control one, at the end, 1 and 5 hours after the end of the infusion. The aggregation has been induced both by ADP and adrenaline. The results are exposed and some pathogenetic hypotesis are suggested.